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Abstract:  
Background & Aims: Hepatitis B virus (HBV) reactivation during or after chemotherapy in 
breast cancer patients has became a remarkable clinical problem. Prophylactic nucleos(t)ide 
analogues (NAs) are recommended for breast patients with hepatitis B surface antigen 
(HBsAg) positive before chemotherapy. We performed an up-to-date meta-analysis to 
compare the efficacy of prophylactic lamivudine use with non-prophylaxis in HBsAg positive 
breast cancer patients undergoing chemotherapy. 
Methods: PubMed, the Cochrane Library and China National Knowledge Infrastructure 
(CNKI) databases were searched for literature until June 2016. Eligible articles that 
comparing the efficacy of prophylactic lamivudine use with non-prophylaxis in HBsAg 
positive breast cancer patients undergoing chemotherapy were identified.  
Results: Eight studies enrolled 709 HBsAg positive breast cancer patients undergoing 
chemotherapy were analyzed. Lamivudine prophylaxis significantly reduces the rates of 
chemotherapy-associated hepatitis B flares in chronic hepatitis B in breast cancer compared 
with patients with non-prophylaxis (odds ratio [OR] = 0.15, 95% confidence interval [CI]: 
0.07-0.35, P < 0.00001). Chemotherapy disruption rates attributed to HBV reactivation in the 
Prophylaxis groups were significant lower than Non-prophylaxis groups (OR = 0.17, 95% CI: 
0.07-0.43, P = 0.0002). Patients with lamivudine prophylaxis have higher risk for 
tyrosine-methionine-aspartate-aspartate (YMDD) mutation than patients with non-prophylaxis 
(OR = 6.33, 95% CI: 1.01-39.60, P = 0.05). 
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 Conclusions: Prophylactic antiviral therapy management is necessary for HBsAg positive 
breast cancer patients undergoing chemotherapy, for especially highly correlates with 
lamivudine-resistant HBV variants with YMDD motif-mutation. 
 
Key words: breast cancer, hepatitis B, reactivation, lamivudine, prophylaxis antiviral therapy 
 
Introduction:   
HBV infection is a global public issue and it is estimated approximately 400 million 
patients suffered chronic HBV infection worldwide (1). China is one of the major epidemic 
countries of HBV in the world. The prevalence of chronic HBV infection in Chinese 
population aged 1-59 is as high as 7.2% when compared with 0.3-0.5% carrier rate within 
some western countries (2, 3).  
HBV reactivation is documented in breast cancer patients receiving anti-cancer 
chemotherapy (4-6). As adjuvant chemotherapy is a basic part for breast cancer treatment, 
HBV reactivation has became a significant clinical problem for those breast cancer patients 
with chronic HBV infection, especially in China which enjoys increasing breast cancer 
incidence with twofold greater than the world average in recent years (7). HBV reactivation 
will result in interruption of chemotherapy schedule which predict uncertain prognosis for 
cancer management and the degree of liver dysfunction attributed to HBV reactivation can be 
asymptomatic, moderate, fulminant, even leaded to hepatic failure or mortality potentially (8). 
Several studies have shown NAs prophylaxis can decrease hepatitis B flare and the severity of 
hepatitis attributed to HBV reactivation (5, 9-11). 
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 In breast oncology, researchers indicate risk factors for hepatitis B flare such as: HBV 
serologic status and chemotherapy regimen have a great influence on reactivation rates which 
varies from 41% to 56% (4, 5). Thus, identifying risk factors can predict different prognosis 
for HBV carrier and guides clinical strategies. However, there are very few review articles 
illustrating the risk for breast cancer. We comprehensively conclude not only viral status and 
traditional chemotherapy regimen, but also emerging targeting drugs “everolimus” associated 
HBV reactivation, which are newly applied in breast cancer chemotherapy. 
In this study, we reviewed the basis for managing HBV reactivation including: risk 
factors, screening and prophylactic antiviral therapy. Moreover, we conducted an up-to-date 
meta-analysis to assess lamivudine prophylaxis efficacy as well as lamivudine prophylaxis 
related drug resistance on HBsAg positive breast cancer patients undergoing chemotherapy 
and propose a practical strategy for management of HBV reactivation. 
 
Overview of HBV reactivation 
The natural course of HBV reactivation depends on the interplay between virus replication 
and host immune control (12). Breast cancer patients with chronic HBV infection (CHB), 
which are refereed as HBsAg positive, antibody to hepatitis B core antigen (anti-HBc) 
positive and HBV DNA ranges from undetectable to over 9 log10 copies/ml, usually have 
hypoimmunity after receiving immunosuppressive chemotherapy. The impaired immunity 
will lead to breaking balance between virus replication and host immune control, active virus 
replication, hepatitis Be antigen (HBeAg) turning seropositive and widespread HBV virus 
infection of hepatocytes (13, 14). When chemotherapy completes, T cells destroy hepatic cells 
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 with HBV infection via cytotoxic effects which are associated with immune reconstitution. 
Furthermore, many studies indicate individuals with cleared or occult HBV infection were 
still at risk for HBV reactivation (15). Patients with cleared HBV infection which is defined as 
HBsAg negative, anti-HBc (IgG) positive, antibody to hepatitis B surface antigen (anti-HBs) 
positive and HBV DNA negative; or with occult HBV infection which is defined as HBsAg 
negative, anti-HBc positive, anti-HBs negative and HBV DNA positive/negative, have 
residual HBV DNA in the hepatocytes (16, 17). In these patients, the immunosuppression 
chemotherapy will disable host immunity on the control of “dormant” HBV replication and 
results in HBV reactivation. HBV reactivation in patients with breast cancer occurs after the 
first 1-6 cycles of chemotherapy (median 3 cycles) and the peak alanine aminotransfease 
(ALT) level emerges following the peak HBV DNA with a time lag of 2-3 weeks (4, 18). 
Some cancer patients experience asymptomatic HBV reactivation accompanied by serum ALT 
increasing during chemotherapy; others may suffer severe fulminant hepatitis and hepatic 
failure which even lead to the death of cancer patients (13). 
Currently, the criteria of HBV reactivation is defined as (1) HBV-DNA level rising (≥10-fold 
increase greater than baseline level or the absolute value of HBV DNA copy exceeds 1×109 
copies/ml); (2) HBV DNA turns from seronegativity to seropositivity while excluding of 
co-infection with hepatitis A, C and D virus (HAV, HCV, HDV). (3) HBsAg seroreversion 
with HBV DNA de novo detection in HBsAg negative/ anti-HBc positive patients. 
HBV-related hepatitis flare is defined as serum ALT is 3-fold increase greater than upper limit 
of normal or ALT absolute value is beyond 100 U/L (ALT ≥ 3-fold of upper limit of normal or 
ALT ≥100 U/L) with the coexisting HBV reactivation (19-21). 
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Risk factors for HBV reactivation in breast cancer patients 
It is significantly important to identify risk factors for HBV reactivation in breast cancer 
patients clinically for adopting effective prevention strategies via assessing these factors. We 
have summarized risk factors for HBV reactivation as following. 
Virus status 
Serum HBV viral load is the most fundamental risk factor of HBV reactivation and it is, 
therefore, thought to be the earliest indicator for HBV reactivation. In a study of 39 HBeAg 
negative breast cancer patients who underwent cytotoxic chemotherapy, HBV reactivation 
preferred in patients serum HBV DNA load is over 3×105 copies/ml (≥ 3×105 copies/ml) (22, 
23). HBsAg positivity and HBeAg positivity further increase the risk for HBV reactivation. 
HBsAg positivity confers approximate 8-fold greater risk for reactivation than HBsAg 
negative patients (24, 25). However, HBeAg positivity is not applied as a risk factor in the 
case universally due to other viral status, for example: HBsAg positivity and detectable HBV 
DNA (20, 26). It should be noted HBeAg low-level and HBeAg seroconversion are highly 
susceptible to have HBV precore/core promoter mutation which is a particular risk 
underestimated (27, 28). Precore/core mutation commonly trigger spontaneous reactivation in 
chronic HBV infection patients which often result in severe liver dysfunction; when meet 
tumors, patients with precore/core mutation tend to occur reactivation with a rate approaching 
60% (29-31). Research shows that intrahepatic covalently closed circular DNA (cccDNA) 
which is replicative intermediate of pregenomic RNA, highly correlates with HBV 
reactivation with a specificity of 100% and an accuracy of 88.9% (32-34). Since persistent 
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 cccDNA is detected in the hepatocyte nucleus, intrahepatic cccDNA level can be used as a 
risk factor for HBV reactivation in patients with cleared HBV infection. In addition, serum 
cccDNA\serum HBV DNA ratio validates as a severity index of HBV reactivation, but further 
studies are required to elucidate different grades of this ratio (35). 
Cytotoxic anthracycline and steroid 
It becomes evident that cytotoxic anthracycline and steroid, acting as an integral part of 
monitoring breast cancer, make a major contribution to HBV reactivation. Cancer patients 
who receive steroid-free chemotherapy have a significant lower HBV reactivation rate. 
Besides their effect on T-cell normal function, researchers indicate a 
glucocorticoid-responsive element residing in HBV DNA (36). This element activated by 
glucocorticoid will simulate HBV-DNA enhancer activity, which in turn promotes HBV 
replication as well as transcription. We do know reactivation is steroid dose- and 
time-dependent without knowing the threshold dose, as steroid is used in combination with 
other chemotherapy regimen frequently (26, 37). 
Breast cancer patients receiving anthracycline-based chemotherapy have higher reactivation 
rates than those receiving anthracycline-free treatment even though two groups accept similar 
dose of steroid (38). Immunosuppression conducted by anthracycline was considered as the 
main cause of HBV reactivation. In addition to immunosuppresion, anthracycline results in 
HBV reactivation via other mechanism. Doxorubicin and epirubicin can mediate HBV DNA 
replication, HBV DNA secretion and HBeAg secretion in HBV-producing cell line (39, 40). 
Furthermore, the enhancement of cell regulator p21 upon doxorubicin treatment increases 
CCAAT/enhancer-binding protein α (C/EBPα) expression and promotes C/EBPα binding with 
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 HBV promoters which results in HBV replication (41). 
Molecular targeted drug everolimus 
Everolimus is one of the mammalian target of rapamycin (mTOR) inhibitors, which is 
currently approved in breast cancer. Three cases, one of breast cancer and two of renal cell 
carcinoma, were reported to have HBV reactivation related to everolimus (42-44). These three 
cases developed into fatal fulminant hepatitis resulted from HBV reactivation. The author had 
also observed one breast cancer case displayed severe hepatitis attributed to 
everolimus-associated HBV reactivation in clinical practice. Strikingly, two cases had 
received “reactivation risk” chemotherapy (sorafenib for renal cell cancer patient and 
adriamycin for breast cancer patient), but neither had HBV reactivation during their 
“reactivation risk” chemotherapy schedule. In HBsAg positive hepatocellular carcinoma 
(HCC) patients, everolimus treatment can increase serum HBV DNA levels which results in 
HBV-related hepatitis flare in 19%-53.8% patients (45, 46). An EVOLVE-1 study of 
everolimus for advanced HCC reported 37% patients had HBV reactivation despite of 
prophylactic antiviral management (47). Everolimus contributes to HBsAg synthesis and 
induces HBV replication in cells (48, 49). However, the hepatitis B exacerbation should be 
attributed to strong immunosuppressive effects of everolimus, as it is commonly used as 
immunity inhibitor after organ transplantation (50, 51).  
Interestingly, the HBV serologic status of the two cases from the foregoing was characterized 
as IgM anti-HBc negative, which indicates they potentially occurred cleared/occult HBV 
infection (52, 53). On the background of cleared/occult HBV infection, the HBV reactivation 
rates occur overtly lower than HBsAg positive patients, even reaching 1% in some clinical 
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 trials (54). Yet, these patients tend to develop de novo HBV-related hepatitis which results in 
higher fulminant hepatic failure rates and mortality. Upon case series, nearly 20%-37.5% of 
patients occurred fatal fulminant hepatitis (55, 56). This scenario of low HBV reactivation 
rates but high fatal fulminant hepatitis risk raises concern and more systematic data is needed 
to illustrate the mechanism of the severity of de novo HBV-related hepatitis. 
 
Prevention and prophylaxis management 
Screening  
Intervention is consequentially inferior to prevention before reactivation aggravates. Thus the 
key in prevention is the screening for patients at risk of reactivation by taking their viral status 
and chemotherapy regimen into consideration. Since a vast portion of cancer patients are not 
aware of their chronic HBV infection and they might not cognize they are at high risk of 
fulminant hepatitis, it is great importance to screen their serologic HBV status given the 
potential poor outcome of reactivation. Although targeted screening can be cost-effective, it is 
not advocated. Thus such universal HBV routine tests are recommended for all candidates 
prior to initiation of chemotherapy by European Association for the Study of the Liver (EASL) 
(57), Asian–Pacific Association for the Study of the Liver (APASL) (58), the Korean 
Association for the Study of the Liver (KASL) (59) and Chinese society of hepatology (CMA) 
(60). The American Association for the Study of the Liver (AASLD) recommends targeted 
screening, that is, patients at high risk for HBV infection should be tested with HBsAg and 
anti-HBc before initiation of chemotherapy (61). Table 1 shows current guidelines for HBV 
reactivation. 
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 If screen is undertaken by clinicians, serologic test including HBsAg and anti-HBc should be 
present. Breast cancer patients, who are HBsAg negative and anti-HBc positive, should be 
tested for HBV DNA in order to distinguish occult hepatitis B infection or cleared hepatitis B 
infection. As for HBsAg positive patients, their further serologic status including: HBV DNA 
level, HBeAg, precore/core mutation and serum cccDNA should be required to determine 
prevention strategies.  
Prophylaxis use of antiviral drugs 
Although antivirus drugs, NAs, have therapeutic effects on HBV reactivation, the liver 
function has significantly deteriorated when we notice severe clinical manifestation as the 
HBV replicates since the very beginning. Such condition potentially missed optimal time 
point for antiviral therapy. Therefore, especially for breast cancer specialists must find the 
optimal time for intervention. According to the recent studies, the intervention strategies can 
be divided into as: (1) prophylactic therapy (early pre-emptive therapy): use antivirus 
medication prior to the start of chemotherapy; (2) pre-emptive therapy (deferred pre-emptive 
therapy): tests HBV DNA regularly and use antivirus medication immediately when HBV 
DNA reaches the “positive” baseline and ALT level is within normal limits; (3) therapeutic 
intervention: use antivirus medication when ALT level rises (62, 63). Recent meta-analyses 
have addressed the efficacy of pre-emptive therapy for HBV reactivation in breast cancer 
patients (9, 64, 65). We also perform a meta-analysis to assess the benefits of prophylactic 
lamivudine for reactivation by adding more data. Based on the HBV reactivation mechanism 
as well as vast clinical data, the early pre-emptive therapy and the deferred pre-emptive 
therapy are better approaches for managing than the delayed intervention therapy. However, it 
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 is remarkable fact that, in deferred pre-emptive therapy strategy, lamivudine was treated at the 
time when HBV DNA “significant rise” defined as: HBV DNA levels 10-fold increase if 
baseline HBV DNA levels 105 copies/mL; HBV DNA levels 100-fold increase or HBV DNA 
levels 105 copies if baseline level <105 copies/mL (66). HBV DNA elevation is the first stage 
of reactivation. Considering that such high HBV DNA levels have met HBV reactivation 
criteria partially and investigators decide lamivudine use by such high HBV DNA levels, we 
insist that deferred pre-emptive therapy is an alternative therapeutic intervention. In fact, two 
randomized controlled studies have proven prophylactic therapy is far more effective than 
pre-emptive therapy in lymphoma patients and the reactivation rate in pre-emptive therapy 
group is close to the rates in therapeutic group (63, 67). 
Prophylaxis management is not requisite for all breast cancer patients undergoing 
chemotherapy. Several guidelines recommend that HBsAg positive or HBV DNA detected 
cancer patients should be tested for baseline HBV DNA levels and use NAs before the 
initiation of chemotherapy regardless of HBV DNA levels (58-61). As for cleared/occult HBV 
infection patients, they have lower risks for reactivation than HBsAg-positive patients when 
expose to chemotherapy. They are recommended to monitor ALT level, HBV DNA and 
HBsAg and be treated with NAs upon confirmation of HBV reactivation (57-59). Considering 
high risks for cleared/occult HBV infection patients such as: everolimus, intense 
anthracycline and steroid, we suggest that these breast cancer patients should receive 
prophylaxis antiviral therapy before the initiation of chemotherapy (68). In addition, 
prophylaxis therapy is expensive and it will, however, lead to the possibility of overtreatment 
for nearly half of the cancer patients without HBV reactivation. We propose that clinicians can 
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 use of risk calculators to decide whether breast cancer patients require prophylaxis antiviral 
therapy or not by estimating HBV DNA level, HBeAg, precore/core mutation, serum cccDNA 
and types of chemotherapy. For instance, researchers establish a predictive model that consists 
of clinical and virological factors to estimate the probability of HBV reactivation in 
lymphoma and breast cancer patients (69). (Figure 1) 
Lamivudine is extensively used as prophylaxis antiviral agent in most studies as it was first 
generation of NAs approved for hepatitis B treatment and its preventative efficacy in 
managing HBV reactivation has been proven in breast cancer patients. However, failure of 
preventative lamivudine was observed during clinical practice. In this study, we have shown 
that lamivudine prophylaxis patients have higher risk to develop 
tyrosine-methionine-aspartate-aspartate (YMDD) mutation than non-prophylaxis. Lamivudine 
has a low barrier to develop drug resistance. Variants in the YMDD motif tend to increasingly 
develop which can lead to its resistance over prolonged course of lamivudine (70). Emergence 
of YMDD mutation abrogates the benefits obtained with prophylaxis lamivudine treatment 
and may cause fatal hepatic failure (61, 71). Clinicians should be aware of YMDD mutation 
rate in prophylactic lamivudine treatment. Furthermore, delayed HBV reactivation after 
lamivudine withdrawal was reported in cancer patients who accepted preventative lamivudine 
until 4 weeks to 3.4 months after cessation of chemotherapy (72, 73). High baseline HBV 
DNA (> 2000 IU/mL) is a predictor of delayed HBV reactivation. Hence, for breast cancer 
patients whose anticipated antiviral duration is long (> 12 months) or pre-chemotherapy HBV 
DNA > 2000 IU/mL, entecavir or tenofovir is recommended and NAs treatment was 
recommended to continue at least 6 months after the cessation of chemotherapy for HBsAg 
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 positive cancer patients undergoing conventional chemotherapy (57-59, 61). 
 
Materials and methods  
Data sources and study selection 
Two independent authors (ZH.L. and L.J.) searched and reviewed citations from the Cochrane 
Library, PubMed and China National Knowledge Infrastructure (CNKI) by use the keywords 
“chemotherapy”, “breast”, “cancer”, “carcinoma”, “HBV”, “reactivation”, “prophylaxis”, 
“preemptive”, “lamivudine”. The search was performed in June 2016 without limitation of 
language and time. This study is restricted to human studies and includes all clinical trials 
regardless of randomized, controlled, prospective and retrospective studies. This study 
excludes: (1) meeting abstract, reviews and case reports; (2) studies do not contain 
prophylaxis and non-prophylaxis groups; (3) studies involved HCV, HDV and human 
immunodeficiency virus co-infection; (4) the studies included patients receiving no 
immunosuppressive chemotherapy. 
Definition  
The criteria of HBV reactivation is defined as (1) HBV-DNA level rising (≥10-fold increase 
greater than baseline level or the absolute value of HBV DNA copy exceeds 1×10^9 
copies/ml); (2) HBV DNA turns from seronegativity to seropositivity while excluding of 
co-infection with HAV, HCV and HDV. (3) HBsAg seroreversion with HBV DNA de novo 
detection in HBsAg negative/anti-HBc positive patients. HBV-related hepatitis flare is defined 
as ALT is 3-fold increase greater than upper limit of normal or ALT absolute value is beyond 
100 U/L (ALT ≥ 3-fold of upper limit of normal or ALT ≥100 U/L) with the coexisting HBV 
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 reactivation. Disruption of chemotherapy was defined as premature termination or a delay of 
chemotherapy over than 8 days between cycles (19-21). 
Data extraction and quality assessment 
By reading the included literature, one researcher (ZH.L.) extracted all data and another 
independent researcher (L.J.) verify the data and the data included details of the studies, 
number of enrolled patients, chemotherapy regimen and outcomes of patients. The study 
quality was independently estimated by two investigators (ZH.L. and L.J.) using the 
Newcastle-Ottawa Scale (NOS). 
Statistical analysis 
We perform meta-analysis by using Review Manager Software version 5.0 for window 
(Cochrane Collaboration, Oxford, UK). Statistical heterogeneity was assessed by the 
chi-squared and I-squared test. In these tests, P < 0.10 was regarded as significant 
heterogeneity. The outcome was measured as odds ratio (OR) with 95% confidence intervals 
(CI). A random effect model was applied for analysis in the cases where significant 
heterogeneity exists. A fixed effect model was applied in other cases. P < 0.05 was used to 
indicate statistical significance. 
 
Result 
Search results and description of studies 
In all, 142 literatures were obtained and screened for retrieval via using the searching strategy 
mentioned above. After screening for title and abstract, 125 studies were excluded and 17 
were retrieved for further assessment. Ultimately, 9 studies were removed by the exclusion 
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 criteria and 8 studies were included by using strict inclusion criteria (5, 66, 74-79). Details on 
study selection are listed in Supplementary Figure 1. 
One study was a randomized controlled study (74); two were retrospective cohort studies (75, 
76) and five were prospective cohort studies (5, 66, 76, 77, 79) of the eight studies. Seven 
studies have compared prophylaxis lamivudine administration with non-prophylaxis 
management (5, 74-79) and one evaluated the efficacy-effectiveness distinction between 
prophylaxis lamivudine management and deferred pre-emptive lamivudine management (66). 
We combine with the concept of therapeutic strategy and deferred pre-emptive strategy as we 
have discussed deferred pre-emptive strategy is another kind of therapeutic strategy above. 
The populations of the eight studies were HBsAg positive and were all Asian, with five from 
China and three from Korea. 
Comparing occurrence rates of hepatitis attributed to HBV reactivation between the 
prophylaxis and non-prophylaxis groups 
The six studies which included 232 patients in the prophylaxis group and 387 patients in the 
non-prophylaxis group, reported hepatitis attributed to HBV reactivation. Meta-analysis 
reveals that there is a significant difference in hepatitis attributed to HBV reactivation 
between lamivudine prophylaxis and non-prophylaxis group (OR = 0.15, 95% CI: 0.07-0.35, 
P < 0.00001) (figure 2). There is no significant heterogeneity among the six studies 
(chi-squared = 2.47, I2 = 0%, P = 0.65). 
Comparing chemotherapy disruption rates attributed to HBV reactivation between the 
prophylaxis and non-prophylaxis groups 
The six studies which included 228 patients in the prophylaxis group and 292 patients in the 
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 non-prophylaxis group reported chemotherapy disruption attributed to HBV reactivation. 
Patients with lamivudine prophylaxis have a significant lower disruption rate when compared 
patients with non-prophylaxis (OR = 0.17, 95% CI: 0.07-0.43, P = 0.0002) (figure 3). No 
significant heterogeneity was observed (chi-squared = 2.36, I2 = 0%, P = 0.67). 
Comparing YMDD mutation rates related to lamivudine prophylaxis between the 
prophylaxis and non-prophylaxis groups 
Only four patients had YMDD mutation in the six studies which include 226 patients in the 
prophylaxis group and 346 patients in the non-prophylaxis group. Patients with lamivudine 
prophylaxis have higher risk for YMDD mutation statistically (OR = 6.33, 95% CI: 
1.01-39.60, P = 0.05) (figure 4). No significant heterogeneity was noted in these data 
(chi-squared = 0.16, I2 = 0%, P = 0.92). 
 
Discussion  
HBV reactivation upon immunosuppressive chemotherapy is strongly associated with hepatic 
impairment as well as chemotherapy disruption, which predicts poor prognosis for breast 
cancer patients and potentially indicates increasing mortality. Thus antiviral strategies are 
addressed to manage HBV reactivation in several studies. This meta-analysis indicates that 
breast cancer patients with prophylaxis management have better outcomes, including lower 
occurrence rates of hepatitis B flares attributed to HBV reactivation and lower chemotherapy 
disruption rates attributed to HBV reactivation, than patients with non-prophylaxis. Thus, 
prophylactic antiviral management is very necessary for HBsAg positive breast cancer 
patients. 
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 In the past, we have focused on patients with lymphoma or undergoing hematopoietic stem 
cell transplantation and efficacy of prophylactic lamivudine use in these patients (80, 81). 
Little attention about prophylactic antiviral management was drawn in breast cancer. In this 
meta-analysis, we have discussed the necessity of antiviral therapy prophylaxis for HBsAg 
positive breast cancer patients. However, there are several obstacles to be addressed. 
According to another meta-analysis, approximately 85% breast cancer patients are 
over-treated with lamivudine for only 15% patients had developed HBV reactivation in the 
non-prophylaxis group (64). Therefore, most HBsAg positive breast cancer patients will 
benefit from a reactivation risk predictive model. Further researches are required to illustrate 
the risk predictive model in breast cancer. 
In addition, we notice patients with lamivudine prophylaxis have higher risk for YMDD 
mutation statistically in our study, while the YMDD mutation rate is no significant difference 
between prophylaxis and non-prophylaxis because of 95% CI: 0.60-48.95 and P = 0.13 in 
another meta-analysis (64). It should be noted three of the four patients had received long 
lamivudine treatment course with duration time over 18 months (75, 76). Prolonged 
lamivudine use can result in increasing likelihood of YMDD mutants. Studies reported that 
YMDD mutation emerged in 24% of chronic HBV infected patients in the first year of 
lamivudine treatment, 38% in the second year, 50% in the third year and 67% in the fourth 
year (70, 82, 83). We suggest that lamivudine should no longer be regarded as first-line 
medicine for prophylactic management, even though we have some available remedial 
measures when HBV YMDD mutants arising. Those NAs such as entecavir and tenofovir 
which have higher barrier to resistance are proved to be more efficient in preventing HBV 
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 reactivation, reducing HBV related mortality and lowering chemotherapy disruption rates than 
lamivudine (84, 85). No matter what, prophylactic antiviral therapy plays a prerequisite 
“escort” role during chemotherapy for those breast cancer patients with CHB (as showed in 
Figure 5). 
Undoubtedly, our study has several limitations to be considered before the practice of our 
findings. First, we conducted this meta-analysis based on eight studies but not on patients’ 
data. Confounding variables such as different chemotherapy schemes, cancer metastasis and 
patients co-morbidities were not taken into account. Second, some studies included had small 
sample sizes. We need more data to evaluate the relationship between lamivudine prophylaxis 
and YMDD mutation rate because of P = 0.05.  
In conclusion, our study showed lamivudine prophylaxis is effective in reducing 
chemotherapy disruption rates attributed to HBV reactivation as well as occurrence rates of 
hepatitis B flares attributed to HBV reactivation for HBsAg positive/or HBsAg negative 
anti-HBc positive breast cancer patients undergoing chemotherapy. So, breast cancer 
specialists should monitor HBV infection situation and NAs such as entecavir and tenofovir 
are suggested as first-line prophylactic medicine for HBV reactivation management.    
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Figure 1: (supplemental file) 
Figure 1 proposed algorithm for the management of HBV reactivation in breast cancer 
patients undergoing chemotherapy. Abbreviations: HBV, hepatitis B virus; HBsAg, 
hepatitis B surface antigen; anti-HBc, hepatitis B core antibody; HBeAg, hepatitis Be antigen; 
anti-HBs, hepatitis B surface antibody; cccDNA, covalently closed circular DNA; LFT, liver 
function test. 
 
Figure 2: (supplemental file) 
Figure 2 Comparison of occurrence rates of hepatitis attributed to HBV reactivation.  
 
Figure 3: (supplemental file) 
Figure 3 Comparison of chemotherapy disruption rates of hepatitis attributed to HBV 
reactivation. 
 
Figure 4: (supplemental file) 
Figure 4 Comparison of YMDD mutation rates related to lamivudine. 
 
Figure 5: (supplemental file) 
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 Figure 5 A cartoon depicting the dynamic situation of HBV virus replication and host 
immune control during chemotherapy with antiviral therapy. 
 
Table 1 Summary of current guidelines for hepatitis B virus reactivation management 
(supplemental file) 
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 United states  
AASLD 2009 (61) 
Europe  
EASL 2012 (57) 
Asian-pacific  
APASL 2015 (58) 
Korea 
KASL 2016 (59) 
China  
CMA 2015 (60) 
Screening 
indication 
Patients who are at 
high risk for HBV 
infection 
All candidates for   
chemotherapy 
All candidates for  
chemotherapy 
All candidates for  
chemotherapy 
All candidates for  
chemotherapy 
Screening 
parameters 
HBsAg and anti-HBc HBsAg and anti-HBc HBsAg and anti-HBc HBsAg, anti-HBc and 
Serum HBV DNA 
HBsAg, anti-HBc and 
Serum HBV DNA 
Screening time  Before chemotherapy Before chemotherapy Before  chemotherapy Before  chemotherapy Before  
chemotherapy 
Indication of 
prophylaxis 
HBV carriers HBsAg (+) HBsAg (+) HBsAg (+) or HBV DNA 
(+) 
HBsAg (+) 
Time of starting 
antiviral 
therapy 
With start of 
chemotherapy 
During  
chemotherapy 
Before  chemotherapy With start of  
chemotherapy 
Before  
chemotherapy 
Antiviral agents Lamivudine or 
telbivudine, if 
anticipated duration is 
short  (<12 mo) 
Tenofovir or entecavir 
if anticipated duration 
if long (> 12 mo)  
Lamivudine for 
HBsAg (+) and HBV 
DNA < 2000 IU/mL 
Entecavir or tenofovir 
for HBsAg (+), HBV 
DNA > 2000 IU/mL 
and (or) lengthy or 
repeated  cycles of 
chemotherapy 
NAs  
(entecavir and tenofovir 
should be considered if 
prolonged antiviral 
therapy is indicated) 
NAs  
(Entecavir or tenofovir 
for HBV DNA > 2000 
IU/mL or lengthy or 
repeated  cycles of  
chemotherapy ) 
NAs 
Duration 
endpoint 
6 mo after cessation of  
chemotherapy  for 
baseline HBV DNA < 
2000 IU/mL 
Until reaching 
treatment endpoints of 
immunocompetent for 
cases of baseline HBV 
DNA > 2000 IU/mL 
12 mo after cessation 
of  chemotherapy 
12 mo after cessation of  
chemotherapy 
6 mo after cessation of  
chemotherapy 
6 mo after cessation of  
chemotherapy 
HBsAg (-) 
anti-HBc (+) 
management  
Not specific Test with ALT and 
HBV DNA,  
Treat with NA upon 
confirmation of 
reactivation regardless 
of anti-HBs 
Test with ALT and HBV 
DNA,  
Treat with NA upon 
confirmation of 
reactivation regardless 
of anti-HBs 
Test with serum HBV 
and HBsAg 
Treat with NA upon 
serum HBV and HBsAg 
reappears 
Not specific  
 Abbreviations: the American Association for the Study of the Liver, AASLD; European Association 
for the Study of the Liver, EASL; Asian–Pacific Association for the Study of the Liver, APASL; the 
Korean Association for the Study of the Liver, KASL; Chinese society of hepatology, CMA; HBV, 
hepatitis B virus; HBsAg, hepatitis B surface antigen; anti-HBc, hepatitis B core antibody; alanine 
aminotransfease ,ALT; nucleos(t)ide analogues, NAs 
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Supplemental Figure 1 Details on study selection of studies included in the meta-analysis. 
Additional records identified 
through other sources (n=12) 
  
Records after duplicates removed 
(n=142) 
Records screened 
(n=142) 
Records excluded 
(n=125) 
Full-text articles assessed for 
eligibility (n=17) 
 
Full-text articles excluded (n=9)   
Review (n=3) 
Not use of lamivudine for 
prophylaxis（n=2） 
No control group（n=4） Studies included in the 
meta-analysis 
（n=8） 
1 randomized controlled study 
2 retrospective cohort studies 
5 prospective cohort studies 
 
Records identified through 
database searching (n=130) 
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Criteria Brief description of how the criteria were handled in the 
meta-analysis 
Reporting of background should 
include 
 
√ The clinical problem Hepatitis B virus reactivation during chemotherapy in breast 
cancer patients has became a remarkable clinic problem. 
Prophylactic nucleos(t)ide analogues are recommended for the 
prevention of HBV reactivation before chemotherapy. The 
efficacy of prophylactic lamivudine use in HBsAg positive breast 
cancer patients undergoing chemotherapy remains to be 
summarized. √ The hypothesis Prophylactic antiviral therapy management is efficient in reducing 
hepatitis attributed to HBV reactivation and chemotherapy 
disruption attributed to HBV reactivation, but increases the risk of 
tyrosine-methionine-aspartate-aspartate mutation. √ Description of study outcomes Observed objects developed HBV reactivation √ Type of exposure or intervention 
used 
lamivudine 
√ Type of study designs used Retrospective cohort studies, prospective cohort studies and a 
randomized controlled study in unselected population √ Study population No restriction. 
Reporting of search strategy should 
include 
 
√ Qualifications of searchers Patients and methods/Data extraction and quality assessment. 
Researchers experienced in systematic reviews, breast cancer and 
infectious diseases. √ Search strategy, including time 
period included in the synthesis and 
keywords 
Patients and methods/ Data sources and study selection. PubMed, 
the Cochrane Library and China National Knowledge 
Infrastructure (CNKI) up to June 2016. Key word: chemotherapy, 
breast, cancer, carcinoma, HBV, reactivation, prophylaxis, 
lamivudine. √ Databases and registries searched PubMed, the Cochrane Library and China National Knowledge 
Infrastructure (CNKI) √ Search software used, name and 
version, including special features 
We did not employ a search software. EndNote X7 was used to 
merge retrieved citations and eliminate duplications √ Use of hand searching We hand-searched bibliographies of retrieved papers for 
additional references, √ List of citations located and those 
excluded, including justifications 
Details of the literature search are presented in the Result/ Search 
results and description of studies.  The citation list is available 
upon request √ Method of addressing articles 
published in languages other than 
English 
We placed no restrictions on language; local scientists fluent in 
the original language of the article were contacted for translation  
√ Method of handling abstracts and 
unpublished studies 
We did not include studies only published as abstracts 
√ Description of any contact with 
authors 
We contacted experts to identify potentially eligible trials, 
published and unpublished. 
Reporting of methods should include  √ Description of relevance or 
appropriateness of studies 
assembled for assessing the 
hypothesis to be tested 
Detailed inclusion and exclusion criteria were described in the 
Patients and methods section.  
√ Rationale for the selection and 
coding of data 
Data extracted from each of the studies were relevant to the 
population characteristics, study design, exposure, outcome, and 
possible effect modifiers of the association. √ Documentation of how data were 
classified and coded 
We expressed results for dichotomous outcomes as relative  
risk (RR) with 95% confidence intervals (CIs) √ Assessment of confounding Not stated  √ Assessment of study quality, 
including blinding of quality 
assessors; stratification or 
regression on possible predictors of 
study results 
Not stated  
√ Assessment of heterogeneity Statistical heterogeneity was assessed by the chi-squared and 
I-squared test. In these tests, P < 0.10 was regarded as significant 
heterogeneity √ Statistical methods (eg, complete 
description of fixed or random 
Not state 
effects models, justification of 
whether the chosen models account 
for predictors of study results, 
dose-response models, or 
cumulative meta-analysis) in 
sufficient detail to be replicated √ Provision of appropriate tables and 
graphics 
In the manuscript  
Reporting of results should include  √ A graph summarizing individual 
study estimates and overall estimate 
See Fig 1. PRISMA statement of search results 
√ A table giving descriptive 
information for each study included 
No 
√ Results of sensitivity testing 
 
No   
√ Indication of statistical uncertainty 
of findings 
The outcome was measured as odds ratio with 95% confidence 
intervals, statistical heterogeneity was assessed by the chi-squared 
and I-squared test. In these tests, P < 0.10 was regarded as 
significant heterogeneity. 
Reporting of discussion should include  √ Quantitative assessment of bias Not stated  √ Justification for exclusion Described in Patients and methods / Data sources and study 
selection √ Assessment of quality of included 
studies 
We thoroughly observed every study and discussed the quality of 
each included study. Only included the well-designed cohort 
studies and randomized controlled studies that meet our criterias. 
Reporting of conclusions should 
include 
 
√ Consideration of alternative 
explanations for observed results 
In the Discussion paragraph 3 we consider the patients had 
received long lamivudine treatment course before prophylaxis 
lamivudine use. Limitations of the meta-analysis should be 
considered. These confounders may alter the result. √ Generalization of the conclusions Our meta-analysis, though with limitations, concludes that 
prophylactic antiviral therapy management is efficient in reducing 
hepatitis attributed to HBV reactivation and chemotherapy 
disruption attributed to HBV reactivation, but increases the risk of 
tyrosine-methionine-aspartate-aspartate mutation. We noted the 
lack of clinical data from Africa, America and Europe. √ Guidelines for future research We recommend future studies on the efficacy of prophylactic use 
of nucleos(t)ide analogues such as entecavir and tenofovir, as 
entecavir and tenofovir is widely used in clinical practice and 
associates with less emergence of drug resistance. √ Disclosure of funding source No separate funding was necessary for the undertaking of this 
systematic review. 
